These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 30270567)

  • 1. GLP-1 receptor agonist added to insulin versus basal-plus or basal-bolus insulin therapy in type 2 diabetes: A systematic review and meta-analysis.
    Castellana M; Cignarelli A; Brescia F; Laviola L; Giorgino F
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3082. PubMed ID: 30270567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Giugliano D; Esposito K
    Diabetes Res Clin Pract; 2019 Aug; 154():101-115. PubMed ID: 31238059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Free and fixed-ratio combinations of basal insulin and GLP-1 receptor agonists versus basal insulin intensification in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Maiorino MI; Chiodini P; Bellastella G; Scappaticcio L; Longo M; Esposito K; Giugliano D
    Diabetes Obes Metab; 2018 Sep; 20(9):2309-2313. PubMed ID: 29732679
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin and Glucagon-Like Peptide 1 Receptor Agonist Combination Therapy in Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Maiorino MI; Chiodini P; Bellastella G; Capuano A; Esposito K; Giugliano D
    Diabetes Care; 2017 Apr; 40(4):614-624. PubMed ID: 28325801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fixed-Ratio Combinations of Basal Insulin and GLP-1RA in the Management of Type 2 Diabetes Mellitus: Highlights from the Literature.
    Lisco G; De Tullio A; Guastamacchia E; Triggiani V
    Endocr Metab Immune Disord Drug Targets; 2021; 21(4):626-646. PubMed ID: 32628602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Basal insulin intensification with GLP-1RA and dual GIP and GLP-1RA in patients with uncontrolled type 2 diabetes mellitus: A rapid review of randomized controlled trials and meta-analysis.
    Lisco G; De Tullio A; Disoteo O; De Geronimo V; Piazzolla G; De Pergola G; Giagulli VA; Jirillo E; Guastamacchia E; Sabbà C; Triggiani V
    Front Endocrinol (Lausanne); 2022; 13():920541. PubMed ID: 36157450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of a glucagon-like peptide-1 receptor agonist added to basal insulin therapy versus basal insulin with or without a rapid-acting insulin in patients with type 2 diabetes: results of a meta-analysis.
    Wysham CH; Lin J; Kuritzky L
    Postgrad Med; 2017 May; 129(4):436-445. PubMed ID: 28294702
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison.
    Jung HN; Cho YK; Min SH; Kim HS; Kim YJ; Park JY; Lee WJ; Jung CH
    Front Endocrinol (Lausanne); 2022; 13():870722. PubMed ID: 35669682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Glucagon-like peptide 1 receptor agonist therapy is more efficacious than insulin glargine for poorly controlled type 2 diabetes: A systematic review and meta-analysis.
    Liu FP; Dong JJ; Yang Q; Xue XZ; Ren ZF; Gan YZ; Liao L
    J Diabetes; 2015 May; 7(3):322-8. PubMed ID: 25047138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials.
    Patoulias D; Stavropoulos K; Imprialos K; Katsimardou A; Kalogirou MS; Koutsampasopoulos K; Zografou I; Papadopoulos C; Karagiannis A; Doumas M
    Diabetes Res Clin Pract; 2019 Dec; 158():107927. PubMed ID: 31733280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Options for intensification of basal insulin in type 2 diabetes: Premeal insulin or short-acting GLP-1 receptor agonists?
    Darmon P; Raccah D
    Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S21-6S27. PubMed ID: 26774016
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-world study of the concomitant use of biphasic insulin aspart 30/70 with GLP-1 receptor agonist versus first-generation basal insulin with GLP-1 receptor agonist in type 2 diabetes.
    Davies M; Alibegovic AC; Anil G; Braae UC; Jensen AB; Nordsborg RB
    Diabet Med; 2024 May; 41(5):e15267. PubMed ID: 38088483
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Why is a combination of basal insulin with a GLP-1 receptor agonist useful in many patients with type 2 diabetes?].
    Nauck M; Wilhelm B
    MMW Fortschr Med; 2017 Jun; 159(Suppl 5):7-15. PubMed ID: 28643293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. De-intensification of basal-bolus insulin regimen after initiation of a GLP-1 RA improves glycaemic control and promotes weight loss in subjects with type 2 diabetes.
    Falcetta P; Nicolì F; Citro F; Ciccarone A; Garofolo M; Del Prato S; Bianchi C
    Acta Diabetol; 2023 Jan; 60(1):53-60. PubMed ID: 36166172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adding prandial GLP-1 receptor agonists to basal insulin: a promising option for type 2 diabetes therapy.
    Goldenberg RM; Berard L
    Curr Med Res Opin; 2018 Jan; 34(1):1-10. PubMed ID: 28836861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of glucose-lowering agents after dual therapy failure in type 2 diabetes: A systematic review and network meta-analysis of randomized controlled trials.
    Zaccardi F; Dhalwani NN; Dales J; Mani H; Khunti K; Davies MJ; Webb DR
    Diabetes Obes Metab; 2018 Apr; 20(4):985-997. PubMed ID: 29205774
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis.
    Eng C; Kramer CK; Zinman B; Retnakaran R
    Lancet; 2014 Dec; 384(9961):2228-34. PubMed ID: 25220191
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meta-analysis of head-to-head clinical trials comparing incretin-based glucose-lowering medications and basal insulin: An update including recently developed glucagon-like peptide-1 (GLP-1) receptor agonists and the glucose-dependent insulinotropic polypeptide/GLP-1 receptor co-agonist tirzepatide.
    Nauck MA; Mirna AEA; Quast DR
    Diabetes Obes Metab; 2023 May; 25(5):1361-1371. PubMed ID: 36700380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fixed-ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß-cell function in people with type 2 diabetes.
    Ferrannini E; Niemoeller E; Dex T; Servera S; Mari A
    Diabetes Obes Metab; 2022 Jun; 24(6):1159-1165. PubMed ID: 35257461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
    Mehta R; Billings LK; Liebl A; Vilsbøll T
    Diabet Med; 2022 Sep; 39(9):e14901. PubMed ID: 35708737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.